Pharmaleads

Iacta Pharmaceuticals, Inc.

Annabelle Reaux-Le Goazigo

Hervé Poras

Michel Wurm

Stéphane Melik Parsadaniantz

The disclosure relates to compounds of formula (I): R1-NH&#x2014;CH(R2)-P(&#x2550;O)(OH)&#x2014;CH2-C(R3)(R4)-CONH&#x2014;C(R5)(R6)-COOR7, where R1 to R7 are as defined in the claims, for use of same in the treatment and/or prevention of ocular inflammation, and more particularly for improving the process of ocular healing. Thus, the compounds of formula (I) are used, in particular, to prevent neovascularisation, or to prevent or treat an ocular inflammation linked to a keratitis, scleritis, episcleritis, uveitis, cataract, synechia, macular oedema, detachment of the retina, ocular hypertension and degeneration of the optical nerve caused by glaucoma.

Aminophosphinic derivatives for preventing and treating eye inflammation

The disclosure relates to a method of treating or preventing eye pain in a subject in need thereof. The method includes administering a compound of formula (I), R&#x2014;NH&#x2014;CH(R)&#x2014;P(&#x2550;O)(OH)&#x2014;CH&#x2014;C(R)(R)&#x2014;CONH&#x2014;C(R)(R)&#x2014;COOR, to the subject.

Growing community of inventors

Maison Alfort, France

Annabelle Reaux-Le Goazigo